213 related articles for article (PubMed ID: 19855097)
1. CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.
Chaudhry AS; Urban TJ; Lamba JK; Birnbaum AK; Remmel RP; Subramanian M; Strom S; You JH; Kasperaviciute D; Catarino CB; Radtke RA; Sisodiya SM; Goldstein DB; Schuetz EG
J Pharmacol Exp Ther; 2010 Feb; 332(2):599-611. PubMed ID: 19855097
[TBL] [Abstract][Full Text] [Related]
2. [Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy].
Yamamoto Y; Takahashi Y; Nishimura S; Ikumi Y; Mishima N; Kagawa Y
Yakugaku Zasshi; 2011; 131(5):809-15. PubMed ID: 21532277
[TBL] [Abstract][Full Text] [Related]
3. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms.
Hung CC; Lin CJ; Chen CC; Chang CJ; Liou HH
Ther Drug Monit; 2004 Oct; 26(5):534-40. PubMed ID: 15385837
[TBL] [Abstract][Full Text] [Related]
4. The association between CYP2C9/2C19 polymorphisms and phenytoin maintenance doses in Asian epileptic patients: A systematic review and meta-analysis
.
Liao K; Liu Y; Ai CZ; Yu X; Li W
Int J Clin Pharmacol Ther; 2018 Jul; 56(7):337-346. PubMed ID: 29628024
[TBL] [Abstract][Full Text] [Related]
5. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.
Scordo MG; Pengo V; Spina E; Dahl ML; Gusella M; Padrini R
Clin Pharmacol Ther; 2002 Dec; 72(6):702-10. PubMed ID: 12496751
[TBL] [Abstract][Full Text] [Related]
6. CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.
Franco V; Perucca E
Expert Opin Drug Metab Toxicol; 2015; 11(8):1269-79. PubMed ID: 26037375
[TBL] [Abstract][Full Text] [Related]
7. Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes.
Sahi J; Shord SS; Lindley C; Ferguson S; LeCluyse EL
J Biochem Mol Toxicol; 2009; 23(1):43-58. PubMed ID: 19202563
[TBL] [Abstract][Full Text] [Related]
8. Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting.
Lee SY; Lee ST; Kim JW
J Biochem Mol Biol; 2007 May; 40(3):448-52. PubMed ID: 17562299
[TBL] [Abstract][Full Text] [Related]
9. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population.
Allabi AC; Gala JL; Horsmans Y
Pharmacogenet Genomics; 2005 Nov; 15(11):779-86. PubMed ID: 16220110
[TBL] [Abstract][Full Text] [Related]
10. Paradoxical urinary phenytoin metabolite (S)/(R) ratios in CYP2C19*1/*2 patients.
Argikar UA; Cloyd JC; Birnbaum AK; Leppik IE; Conway J; Kshirsagar S; Oetting WS; Klein EC; Remmel RP
Epilepsy Res; 2006 Sep; 71(1):54-63. PubMed ID: 16815679
[TBL] [Abstract][Full Text] [Related]
11. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients.
Kesavan R; Narayan SK; Adithan C
Eur J Clin Pharmacol; 2010 Jul; 66(7):689-96. PubMed ID: 20390258
[TBL] [Abstract][Full Text] [Related]
12. Influence of the CYP2C9 AND CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India.
Rosemary J; Surendiran A; Rajan S; Shashindran CH; Adithan C
Indian J Med Res; 2006 May; 123(5):665-70. PubMed ID: 16873909
[TBL] [Abstract][Full Text] [Related]
13. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.
Kidd RS; Curry TB; Gallagher S; Edeki T; Blaisdell J; Goldstein JA
Pharmacogenetics; 2001 Dec; 11(9):803-8. PubMed ID: 11740344
[TBL] [Abstract][Full Text] [Related]
14. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.
van der Weide J; Steijns LS; van Weelden MJ; de Haan K
Pharmacogenetics; 2001 Jun; 11(4):287-91. PubMed ID: 11434505
[TBL] [Abstract][Full Text] [Related]
15. Individualized phenytoin therapy for Japanese pediatric patients with epilepsy based on CYP2C9 and CYP2C19 genotypes.
Yamamoto Y; Takahashi Y; Imai K; Miyakawa K; Ikeda H; Ueda Y; Yamaguchi T; Nasu H; Ohtani H; Shigematsu H; Kagawa Y; Inoue Y
Ther Drug Monit; 2015 Apr; 37(2):229-35. PubMed ID: 25162219
[TBL] [Abstract][Full Text] [Related]
16. 5'-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients.
Takahashi H; Ieiri I; Wilkinson GR; Mayo G; Kashima T; Kimura S; Otsubo K; Echizen H
Blood; 2004 Apr; 103(8):3055-7. PubMed ID: 15070684
[TBL] [Abstract][Full Text] [Related]
17. Linkage disequilibrium between the CYP2C19*2,*17 and CYP2C9*1 alleles and impact of VKORC1, CYP2C9, CYP2C19 gene polymorphisms and gene-gene interactions on warfarin therapy.
Khalighi K; Cheng G; Mirabbasi S; Khalighi B; Wu Y; Fan W
J Thromb Thrombolysis; 2017 Jan; 43(1):124-129. PubMed ID: 27743182
[TBL] [Abstract][Full Text] [Related]
18. Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms.
Dorado P; López-Torres E; Peñas-Lledó EM; Martínez-Antón J; Llerena A
Pharmacogenomics J; 2013 Aug; 13(4):359-61. PubMed ID: 22641027
[TBL] [Abstract][Full Text] [Related]
19. CYP2C9 promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in CYP2C9*8-mediated effects.
Cavallari LH; Vaynshteyn D; Freeman KM; Wang D; Perera MA; Takahashi H; Drozda K; Patel SR; Jeong H
Pharmacogenet Genomics; 2013 Apr; 23(4):228-31. PubMed ID: 23376925
[TBL] [Abstract][Full Text] [Related]
20. The effect of genetic polymorphisms of cytochrome P450 CYP2C9, CYP2C19, and CYP2D6 on drug-resistant epilepsy in Turkish children.
Seven M; Batar B; Unal S; Yesil G; Yuksel A; Guven M
Mol Diagn Ther; 2014 Apr; 18(2):229-36. PubMed ID: 24338437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
